“Presentation of anxiety symptoms in patients with [major depressive disorder] is typically more complex to successfully treat with currently available medications,” Melissa Fickey, MD, founder of Embracing Life Wellness Center, said in a news release from Neuronetics.
The company tested its NeuroStar advanced therapy for mental health device on 664 patients diagnosed with major depressive disorder and found 65.5 percent of them showed a clinically meaningful response to the treatment.
In May, the FDA approved Neuronetics’ device for adjunct treatment of adults with obsessive compulsive disorder.
At the Becker's Fall Behavioral Health Summit, taking place November 4–5 in Chicago, behavioral health leaders and executives will explore strategies for expanding access to care, integrating services, addressing workforce challenges and leveraging innovation to improve outcomes across the behavioral health continuum. Apply for complimentary registration now.
